hIL4/hIL4R

Fig1. Analysis of hIL4 expression in serum by ELISA. The homozygous KI mice express hIL4 in serum after treatment with concanavalin.

Fig2. Analysis of hIL4R expression in the spleen by FACS. The homozygous KI mice express hIL4R in the spleen, and the WT mice only express mIL4R.

Fig3. Evaluation of an Anti-huIL4Ra mAb in the OXA-Induced Atopic Dermatitis Model in hIL4/hIL4Ra dKI Mice. Both dupilumab and Dexamethasone ameliorate overall atopic dermatitis activity in OXA - challenged ears, but only Dexamethasone worked in back skin. (In cooperation with CrownBio)

Fig4. Dupilumab significantly mitigates inflammatory cell infiltration in lesioned ear. (In cooperation with CrownBio) 

Note: Inflammatory cell infiltration is indicated by black arrows, 10X images

Fig5. Low dose dupilumab significantly mitigates inflammatory cell infiltration in lesioned skin.  (In cooperation with CrownBio) 

Note: Inflammatory cell infiltration is indicated by black arrows, 10X images

Fig6. Dexamethasone and dupilumab treatments are well tolerated. Both significantly reduced IgE levels in serum but not spleen weight. (In cooperation with CrownBio) 

Ordinary one-way ANOVA were applied for analysis compared to Isotype group, *p<0.05, **p<0.01, *** p<0.001.

Fig7. Repeated OXA-induced Th2 cytokine production (hIL-4 elevation) and dupilumab treatment significantly reduces IL-6 and KC/GRO levels in lesioned ear. (In cooperation with CrownBio) 

Ordinary one-way ANOVA were applied for analysis compared to Isotype group, *p<0.05, **p<0.01, *** p<0.001.

Fig8. Repeated OXA-induced Th2 cytokine production (hIL-4 elevation) and dupilumab treatment significantly reduces IL-5 and IL-2 levels in lesioned skin. (In cooperation with CrownBio) 

Ordinary one-way ANOVA were applied for analysis compared to Isotype group, *p<0.05, **p<0.01, *** p<0.001.